Table of Contents


Documents in this background package include:

Memoramdum  [WORD] [PDF] [HTML]


General background document:

TAB 1       Endpoints that have supported cancer drug approval (JCO article)


Prostate Cancer Endpoints Workshop Summary

TAB 2       Monday Morning  [WORD] [PDF] [HTML]

Introductory Overview: Endpoints to Measure Therapeutic Efficacy in Prostate Cancer

TAB 3       Monday Afternoon  [WORD] [PDF] [HTML]

Primary Treatment (Neoadjuvant and Adjuvant) and Hormone-Sensitive Prostate Cancer

TAB 4       Tuesday Morning [WORD] [PDF] [HTML]

Hormone-Refractory Prostate Cancer


Prostate Cancer Endpoint Proposal

TAB 5       ASCO abstract: Stewart A, et al.  “The Clinical Significance of a PSA Nadir > 0.2 to Patients With a Rising Post-operative or Post-radiation PSA Treated with Androgen Deprivation”